Skip to main content

Advertisement

Table 1 Participant characteristics

From: A cross-sectional study of pain sensitivity, disease-activity assessment, mental health, and fibromyalgia status in rheumatoid arthritis

   Whole study group Fibromyalgia classification
   Median (IQR) or % Yes No
N   50 24 26
Female   76% 75% 77%
Age   60 (54–69) 58 (54–66) 63 (54–70)
Current smoker   21% 26% 17%
Analgesia Any 69% 71% 65%
  Paracetamol 63% 71% 54%
  NSAID 16% 17% 15%
  Opiate 37% 38% 35%
DMARD Methotrexate 59% 50% 65%
  Sulfasalazine 22% 15% 25%
  Other nonbiologic DMARD 36% 40% 30%
  Combination nonbiologic DMARD 24% 29% 15%
Biologic therapy   12% 8% 16%
Combination therapy 31% 33% 27%
Glucocorticosteroid   20% 15% 21%
Pressure pain threshold    
  Knee 173 (119–287) 133 (58–181)** 239 (169–470)
  Tibia 140 (98–246) 108 (61–167)** 187 (122–337)
  Sternum 155 (85–211) 111 (70–175)** 179 (149–256)
  1. Demographics of the entire study group and a comparison between participants that did or did not satisfy fibromyalgia-classification criteria. Other nonbiologic DMARDs were azathioprine (n = 2), leflunomide (n = 4), gold (n = 3), hydroxychloroquine (n = 6), and cyclosporin (n = 3). Biologic therapies were antitumor-necrosis factor agents (n=4), rituximab (n=1), or abatacept (n=1). Combination DMARDs; two or more biologic or nonbiologic DMARDs. **P < 0.01 (compared with participants who did not satisfy criteria for fibromyalgia).